Table 3.

Other antiviral treatment for Covid-19.

Antiviral Drugs	Dosage forms	Dose	Indications	Benefits	Drawbacks
Remdesivir	Solution/Powder	Intravenous/200 mg loading dose, followed by 100 mg once daily for 5–10 days for adults	COVID-19 patients of ≥12 years requiring hospitalization	It reduces the requirement of high level of respiratory (oxygen) support. There is no evidence of resistance development upon its long term exposure	Signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat were noticed during or after its injection
Favipiravir	Film-coated tablet	Oral/1800 mg/dose twice a day on the first day; followed by 800 mg/dose twice a day for 7–10 days for adults	COVID-19	Favipiravir provides multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy	It has poor pharmacokinetic profile
Molnupiravir		800 mg PO q12hr for 5 days	Emergency use authorization issued for treatment of mild-to-moderate (COVID-19) in adults testing positive for severe acute respiratory syndrome (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19 (hospitalization or death) after COVID-19	It has quick onset of action, a wide therapeutic window, excellent tolerance with a good safety profile, fewer adverse reactions and good tolerability due to its better bioavailability; quick clearance of SARs-COV-2; & no accumulative toxicity	Emergency use
Galidesivir				Galidesivir an adenosine nucleoside analog phase I clinical trials, including against SARS COV-2 Its IM injection or IV infusion is safe and generally well tolerated	In-vitro and in-vivo activities of Galidesivir are restricted to RNA of human public health concern. Its trial has not been designed or sized to demonstrate clinical efficacy